SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending as traders closely monitor high volatility and a sharp pullback, with the community actively debating whether recent price swings are driven by index rebalancing or underlying fundamental concerns about AI power infrastructure demand. Discussions are polarized between investors viewing the drop as a compelling buying opportunity for a critical grid-stabilization play and skeptics questioning its elevated valuation and future growth scalability.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as shareholders react to a recent investor presentation and ongoing focus on the rapid uptake of Recorlev, with the community actively debating the company's valuation, potential for share price appreciation, and the long-term prospects of the XP-8121 Phase 3 pipeline. Investors are closely monitoring management's execution on profitability goals and operational spending while maintaining bullish outlooks based on consistent revenue growth and the company's proprietary drug-delivery technology.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotech is experiencing a sharp rotation of capital as investors pivot away from tech and AI, fueling significant momentum for the sector. Community sentiment is mixed between bullish enthusiasm over potential M&A activity and breakthrough trial data, and concerns regarding heightened volatility in clinical-stage companies.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is capturing significant investor attention as market participants navigate extreme volatility driven by persistent geopolitical tensions in the Strait of Hormuz and contradictory reports surrounding potential ceasefire negotiations. The community remains deeply divided, with many traders analyzing the company's strong FCF potential and debt-reduction progress while others caution against the impact of macro-driven price swings and the risks associated with betting on sensitive energy-sector headlines.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending due to heightened institutional accumulation and excitement surrounding the company's progress with NXC-201, as index funds and major firms continue to build positions ahead of key milestones and potential regulatory catalysts. Community members are closely tracking trial enrollment updates and regulatory pathways, with many viewing the company as a prime candidate for strategic acquisition due to its disruptive CAR-T technology.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is currently trending amidst a highly polarized community debate, with some traders actively looking for bullish reversals and potential 10x gains, while a vocal contingent of investors dismisses the asset as a scam or a failing pump-and-dump scheme. Discussion is further fueled by speculative chatter regarding potential future ETF applications and broader meme coin sector trends, leading to sharp disagreements over the coin's long-term viability versus its perceived lack of utility.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing increased market attention driven by positive clinical data and high levels of institutional ownership, leading to community debate over potential M&A activity and management's effectiveness. Traders are closely monitoring key technical levels and unusual options activity as participants weigh the company's growth outlook against lingering frustration over historical price volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is currently a focal point for the community due to its upcoming inclusion in the Russell 3000 index, which investors are eyeing as a potential catalyst for institutional demand. While the stock has faced recent volatility and ongoing debate regarding its long-term project economics, bulls remain focused on the company's strong cash position, lack of debt, and the potential of its Brimstone and Vortex drill results.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is trending as investors favor it as a defensive, income-focused anchor during market volatility, with active community debate over its role in taxable versus tax-advantaged accounts. Key catalysts include the recent quarterly dividend announcement and an ongoing focus on its rebalanced holdings, which have sparked discussions about the balance between defensive dividend growth and the broader market's tech-driven rallies.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival Corp is trending as investors weigh the company's robust quarterly earnings and record booking demand against ongoing geopolitical instability in the Strait of Hormuz and volatile oil prices. The community is actively debating the stock's valuation disconnect, with many bulls interpreting recent price fluctuations as market manipulation and a prime buying opportunity, while others remain cautious due to broader macro headwinds and potential risks related to regional conflict.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Asian ETFs in Jeopardy Amid the War & Tariff Double Whammy?

Asian ETFs are under pressure as surging oil prices and new U.S. tariffs trigger market turmoil and sharp fund outflows across the region.

South Korea's $350B U.S. Investment Pledge: ETFs That Could Gain

South Korea's $350B U.S. investment pledge could lift the country's export momentum while boosting key U.S. sectors. Here are some ETFs that may benefit.

South Korea ETFs: Quiet AI Winners

South Korea ETFs are surging as AI-driven semiconductor demand fuels market highs, strong earnings momentum and bullish outlook for Korean equities.



Should You Bet on South Korea ETFs After the Kospi Rally?

South Korea's Kospi hit record highs on AI-driven semiconductor strength and rising foreign inflows. With growth forecasts improving, is the rally in South Korea ETFs just getting started?

Best-Performing Country ETFs of 2025

EWY, GREK, EZA, EWP and EPOL surged in 2025 as international ETFs beat U.S. peers, due to cheaper valuations, policy stimulus and diversified market exposure.

Top-Performing International ETFs of 2025

International ETFs like VEA, EZU & EEM outshone U.S. peers in 2025 as cheaper valuations, diversified exposure, and stimulus measures drove substantial gains.

Asia ETF (AIA) Hits New 52-Week High

AIA hit a 52-week high, surging 45.4% from its low as Asia-Pacific markets ride global trade and rate-cut optimism.

Asian Economies Brace For Export Hit As US Tariff Effects Begin To Bite

Equity

Analysts warn that rising U.S. inflation and weaker consumer demand could further dampen import volumes, posing new risks for Asia’s growth. 

iShares Trust - iShares Asia 50 ETF

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$138.00
Prev Close	$140.46
Open	$136.35
Dividend Yield	N/A
50-Day Moving Average	$134.36
Beta	N/A
Avg. Volume	648,425.35
PE Ratio	N/A

52-Week High	$150.83
52-Week Low	$80.08
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

AIAiShares Asia 50 ETF

Latest AIA News